Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

BACKGROUND Combined chemotherapy with irinotecan and cisplatin (IP) is active in patients with nonsmall cell lung carcinoma (NSCLC). However, the optimal administration schedule needs to be defined to maximize its synergic effect. The authors evaluated the efficacy, toxicity, and pharmacokinetics (P...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2006-02, Vol.106 (4), p.873-880
Hauptverfasser:	Han, Ji‐Youn, Lim, Hyeong‐Seok, Lee, Dae Ho, Ju, So Young, Lee, Sung Young, Kim, Hyae Young, Park, Yong‐Hoon, Park, Chun Gun, Lee, Jin Soo
Format:	Artikel
Sprache:	eng
Schlagworte:	administration sequence Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - analogs & derivatives Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology cisplatin Cisplatin - administration & dosage Drug Administration Schedule Female Humans Infusions, Intravenous irinotecan Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical sciences Middle Aged nonsmall cell lung carcinoma Pneumology Sex Factors Treatment Outcome Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!